Autopsy report · NCT03328936
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Hematopoietic Cell Transplantation Recipient; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
- Interventions
- Laboratory Biomarker Analysis; Melphalan Hydrochloride; Melphalan Hydrochloride; Pharmacological Study
- Participants
- 0
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.